118 related articles for article (PubMed ID: 9360843)
21. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
22. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
Møller MB; Gerdes AM; Skjødt K; Mortensen LS; Pedersen NT
Clin Cancer Res; 1999 May; 5(5):1085-91. PubMed ID: 10353742
[TBL] [Abstract][Full Text] [Related]
23. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
24. [Expression of p21 WAF1/CIP1 protein in colorectal cancers: study of its relation to p53 mutation and Ki67 antigen expression].
Chapusot C; Assem M; Martin L; Chalabreyssse L; Benhamiche AM; Lignier MA; Chauffert B; Teyssier JR; Faivre J; Piard F
Pathol Biol (Paris); 2001 Mar; 49(2):115-23. PubMed ID: 11317955
[TBL] [Abstract][Full Text] [Related]
25. Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.
Kamata H; Mitani S; Fujiwara M; Aoki N; Okada S; Mori S
Clin Exp Med; 2007 Jun; 7(2):39-46. PubMed ID: 17609875
[TBL] [Abstract][Full Text] [Related]
26. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression.
Ohshima K; Haraoka S; Fujiki T; Yoshioka S; Suzumiya J; Kanda M; Kikuchi M
Pathol Int; 1999 Jun; 49(6):506-12. PubMed ID: 10469393
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
Slebos RJ; Baas IO; Clement M; Polak M; Mulder JW; van den Berg FM; Hamilton SR; Offerhaus GJ
Br J Cancer; 1996 Jul; 74(2):165-71. PubMed ID: 8688317
[TBL] [Abstract][Full Text] [Related]
28. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers.
Sinicrope FA; Roddey G; Lemoine M; Ruan S; Stephens LC; Frazier ML; Shen Y; Zhang W
Clin Cancer Res; 1998 May; 4(5):1251-61. PubMed ID: 9607584
[TBL] [Abstract][Full Text] [Related]
29. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
[TBL] [Abstract][Full Text] [Related]
30. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations.
Villuendas R; Piris MA; Algara P; Sánchez-Beato M; Sánchez-Verde L; Martinez JC; Orradre JL; García P; Lopez C; Martinez P
Blood; 1993 Nov; 82(10):3151-6. PubMed ID: 8219204
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.
Wong NA; Mayer NJ; Anderson CE; McKenzie HC; Morris RG; Diebold J; Mayr D; Brock IW; Royds JA; Gilmour HM; Harrison DJ
Hum Pathol; 2003 Jun; 34(6):580-8. PubMed ID: 12827612
[TBL] [Abstract][Full Text] [Related]
32. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx.
Nadal A; Jares P; Cazorla M; Fernández PL; Sanjuan X; Hernandez L; Pinyol M; Aldea M; Mallofré C; Muntané J; Traserra J; Campo E; Cardesa A
J Pathol; 1997 Oct; 183(2):156-63. PubMed ID: 9390027
[TBL] [Abstract][Full Text] [Related]
33. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
34. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene.
Facher EA; Becich MJ; Deka A; Law JC
Cancer; 1997 Jun; 79(12):2424-9. PubMed ID: 9191533
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
36. Studies of the p53 gene mutation in Saudi non-Hodgkin's lymphoma.
Ahmad MF; Nasrin N; Akhtar M; Hannan MA
Cancer Lett; 1996 Jul; 104(2):225-31. PubMed ID: 8665492
[TBL] [Abstract][Full Text] [Related]
37. Expression of p21WAF1/CIP1 in soft tissue sarcomas: a comparative immunohistochemical study with p53 and Ki-67.
Pindzola JA; Palazzo JP; Kovatich AJ; Tuma B; Nobel M
Pathol Res Pract; 1998; 194(10):685-91. PubMed ID: 9820864
[TBL] [Abstract][Full Text] [Related]
38. Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis.
Cho JH; Kim WH
Pathol Res Pract; 1998; 194(5):309-17. PubMed ID: 9651943
[TBL] [Abstract][Full Text] [Related]
39. Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
Gaidano G; Vivenza D; Forconi F; Capello D; Gloghini A; Bhatia K; Gutierrez M; Gallicchio M; Avanzi GC; Fassone L; Ariatti C; Buonaiuto D; Cingolani A; Saglio G; Tirelli U; Larocca LM; Dalla-Favera R; Carbone A
Genes Chromosomes Cancer; 2000 Feb; 27(2):177-82. PubMed ID: 10612806
[TBL] [Abstract][Full Text] [Related]
40. [Value of protein 53 expression in lymphoma. Its correlation with genetic mutations].
Echezarreta G; Marcos B; Sanz C; Martínez B; Benítez J; Oliva H; Rivas C
Sangre (Barc); 1997 Oct; 42(5):369-75. PubMed ID: 9424736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
